Aligos Therapeutics (ALGS) Competitors $9.66 0.00 (0.00%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$9.48 -0.18 (-1.86%) As of 03/27/2025 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALGS vs. SEPN, CADL, DSGN, AVIR, ZYBT, CRVS, MBX, IMMP, PRME, and SLRNShould you be buying Aligos Therapeutics stock or one of its competitors? The main competitors of Aligos Therapeutics include Septerna (SEPN), Candel Therapeutics (CADL), Design Therapeutics (DSGN), Atea Pharmaceuticals (AVIR), Zhengye Biotechnology (ZYBT), Corvus Pharmaceuticals (CRVS), MBX Biosciences (MBX), Immutep (IMMP), Prime Medicine (PRME), and Acelyrin (SLRN). These companies are all part of the "pharmaceutical products" industry. Aligos Therapeutics vs. Septerna Candel Therapeutics Design Therapeutics Atea Pharmaceuticals Zhengye Biotechnology Corvus Pharmaceuticals MBX Biosciences Immutep Prime Medicine Acelyrin Septerna (NASDAQ:SEPN) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and risk. Which has higher valuation and earnings, SEPN or ALGS? Septerna has higher earnings, but lower revenue than Aligos Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSepterna$981K284.70N/AN/AN/AAligos Therapeutics$3.95M14.97-$87.68M-$20.90-0.46 Does the MarketBeat Community believe in SEPN or ALGS? Aligos Therapeutics received 23 more outperform votes than Septerna when rated by MarketBeat users. However, 83.33% of users gave Septerna an outperform vote while only 66.67% of users gave Aligos Therapeutics an outperform vote. CompanyUnderperformOutperformSepternaOutperform Votes583.33% Underperform Votes116.67%Aligos TherapeuticsOutperform Votes2866.67% Underperform Votes1433.33% Do analysts prefer SEPN or ALGS? Septerna currently has a consensus target price of $34.00, indicating a potential upside of 440.54%. Aligos Therapeutics has a consensus target price of $70.00, indicating a potential upside of 624.64%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aligos Therapeutics is more favorable than Septerna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Septerna 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Aligos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor SEPN or ALGS? In the previous week, Aligos Therapeutics had 1 more articles in the media than Septerna. MarketBeat recorded 4 mentions for Aligos Therapeutics and 3 mentions for Septerna. Septerna's average media sentiment score of 1.89 beat Aligos Therapeutics' score of 0.47 indicating that Septerna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Aligos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is SEPN or ALGS more profitable? Septerna has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,283.19%. Septerna's return on equity of 0.00% beat Aligos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets SepternaN/A N/A N/A Aligos Therapeutics -1,283.19%-114.34%-64.58% Do institutionals & insiders hold more shares of SEPN or ALGS? 60.4% of Aligos Therapeutics shares are held by institutional investors. 8.8% of Aligos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummarySepterna and Aligos Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Remove Ads Get Aligos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALGS vs. The Competition Export to ExcelMetricAligos TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.06M$3.04B$5.64B$8.06BDividend YieldN/A1.54%4.57%4.01%P/E Ratio-0.7329.2923.1319.03Price / Sales14.97436.17383.8993.17Price / CashN/A168.6838.1634.64Price / Book0.323.956.944.33Net Income-$87.68M-$71.95M$3.20B$247.06M7 Day Performance-10.14%-3.76%-2.33%-0.37%1 Month Performance-42.74%-10.33%2.84%-3.85%1 Year Performance-60.57%-27.15%10.75%1.27% Aligos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALGSAligos Therapeutics4.003 of 5 stars$9.66flat$70.00+624.6%-60.5%$59.06M$3.95M-0.7390Gap DownSEPNSepterna2.3883 of 5 stars$6.37+7.6%$34.00+433.8%N/A$282.85M$981,000.000.00N/AEarnings ReportUpcoming EarningsNews CoveragePositive NewsCADLCandel Therapeutics2.7293 of 5 stars$8.66+7.4%$21.00+142.5%+351.3%$281.24M$120,000.00-5.0160DSGNDesign Therapeutics2.008 of 5 stars$4.93+6.0%$8.00+62.3%+7.2%$279.84MN/A-5.8040Gap UpAVIRAtea Pharmaceuticals2.6485 of 5 stars$3.20-0.6%$6.88+115.0%-24.5%$273.68MN/A-1.5570ZYBTZhengye BiotechnologyN/A$5.80+18.9%N/AN/A$273.56M$189.75M0.00278News CoverageHigh Trading VolumeCRVSCorvus Pharmaceuticals2.3133 of 5 stars$4.25-1.4%$12.38+191.2%+88.3%$273.09MN/A-4.5730Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageMBXMBX Biosciences1.5304 of 5 stars$8.13+3.0%$37.25+358.2%N/A$271.74MN/A0.0036IMMPImmutep1.7606 of 5 stars$1.84-2.1%$8.50+362.0%-23.8%$267.83M$5.14M0.002,021Positive NewsGap DownPRMEPrime Medicine2.8713 of 5 stars$2.03+4.1%$13.38+558.9%-70.4%$266.26M$2.98M-0.99234SLRNAcelyrin3.1741 of 5 stars$2.64-4.0%$9.60+263.6%-60.9%$265.87MN/A-1.07135Positive News Remove Ads Related Companies and Tools Related Companies Septerna Competitors Candel Therapeutics Competitors Design Therapeutics Competitors Atea Pharmaceuticals Competitors Zhengye Biotechnology Competitors Corvus Pharmaceuticals Competitors MBX Biosciences Competitors Immutep Competitors Prime Medicine Competitors Acelyrin Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALGS) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALGS Stock Free ALGS Stock Alerts